The Experts below are selected from a list of 102 Experts worldwide ranked by ideXlab platform
Stefania Milazzo - One of the best experts on this subject based on the ideXlab platform.
-
The Cochrane Library - Laetrile treatment for cancer
Cochrane Database of Systematic Reviews, 2015Co-Authors: Stefania Milazzo, Markus HorneberAbstract:Background Laetrile is the name for a semi-synthetic compound which is chemically related to amygdalin, a cyanogenic glycoside from the kernels of apricots and various other species of the genus Prunus. Laetrile and amygdalin are promoted under various names for the treatment of cancer although there is no evidence for its efficacy. Due to possible cyanide poisoning, Laetrile can be dangerous. Objectives To assess the alleged anti-cancer effect and possible adverse effects of Laetrile and amygdalin. Search methods We searched the following databases: CENTRAL (2014, Issue 9); MEDLINE (1951-2014); EMBASE (1980-2014); AMED; Scirus; CINAHL (all from 1982-2015); CAMbase (from 1998-2015); the MetaRegister; the National Research Register; and our own files. We examined reference lists of included studies and review articles and we contacted experts in the field for knowledge of additional studies. We did not impose any restrictions of timer or language. Selection criteria Randomized controlled trials (RCTs) and quasi-RCTs. Data collection and analysis We searched eight databases and two registers for studies testing Laetrile or amygdalin for the treatment of cancer. Two review authors screened and assessed articles for inclusion criteria. Main results We located over 200 references, 63 were evaluated in the original review, 6 in the 2011 and none in this update. However, we did not identify any studies that met our inclusion criteria. Authors' conclusions The claims that Laetrile or amygdalin have beneficial effects for cancer patients are not currently supported by sound clinical data. There is a considerable risk of serious adverse effects from cyanide poisoning after Laetrile or amygdalin, especially after oral ingestion. The risk–benefit balance of Laetrile or amygdalin as a treatment for cancer is therefore unambiguously negative.
-
Laetrile treatment for cancer
Cochrane Database of Systematic Reviews, 2015Co-Authors: Stefania Milazzo, Markus HorneberAbstract:BACKGROUND: Laetrile is an unconventional therapy which has been used illegally for decades by cancer patients who together with some alternative therapists claim its effectiveness as an anti-cancer treatment. It has been often referred to as amygdalin, although the two are not the same. OBJECTIVES: The aim of this review was to assess the alleged anti-cancer effect and the possible harms of Laetrile as a sole or adjunctive therapy in cancer treatment. SEARCH STRATEGY: We searched The Cochrane Central Register of Controlled Trials (CENTRAL); MEDLINE (from 1951); EMBASE (from 1980); Allied and Complementary Medicine (AMED), Scirus, CancerLit, CINAHL (all from 1982); CAMbase (from 1998); the MetaRegister; the National Research Register and our own files. No language restrictions were imposed. SELECTION CRITERIA: Randomized clinical trials (RCTs) and non randomized controlled clinical trials (non-RCTs). DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed trials for inclusion in the review, assessed study quality and extracted data. MAIN RESULTS: No RCTs or non-RCTs were found, so no abstraction of outcome data could be performed in this systematic review AUTHORS' CONCLUSIONS: The claim that Laetrile has beneficial effects for cancer patients is not supported by data from controlled clinical trials. This systematic review has clearly identified the need for randomised or controlled clinical trials assessing the effectiveness of Laetrile or amygdalin for cancer treatment.
-
Laetrile treatment for cancer.
The Cochrane database of systematic reviews, 2011Co-Authors: Stefania Milazzo, Stephane Lejeune, Edzard Ernst, Katja Boehm, Markus HorneberAbstract:Laetrile is the name for a semi-synthetic compound which is chemically related to amygdalin, a cyanogenic glycoside from the kernels of apricots and various other species of the genus Prunus. Laetrile and amygdalin are promoted under various names for the treatment of cancer although there is no evidence for its efficacy. Due to possible cyanide poisoning, Laetrile can be dangerous. To assess the alleged anti-cancer effect and possible adverse effects of Laetrile and amygdalin. We searched the following databases: CENTRAL (2011, Issue 1); MEDLINE (1951-2011); EMBASE (1980-2011); AMED; Scirus; CancerLit; CINAHL (all from 1982-2011); CAMbase (from 1998-2011); the MetaRegister; the National Research Register; and our own files. We examined reference lists of included studies and review articles and we contacted experts in the field for knowledge of additional studies. We did not impose any restrictions of timer or language. Randomized controlled trials (RCTs) and quasi-RCTs. We searched eight databases and two registers for studies testing Laetrile or amygdalin for the treatment of cancer. Two review authors screened and assessed articles for inclusion criteria. We located over 200 references, 63 were evaluated in the original review and an additional 6 in this update. However, we did not identify any studies that met our inclusion criteria. The claims that Laetrile or amygdalin have beneficial effects for cancer patients are not currently supported by sound clinical data. There is a considerable risk of serious adverse effects from cyanide poisoning after Laetrile or amygdalin, especially after oral ingestion. The risk-benefit balance of Laetrile or amygdalin as a treatment for cancer is therefore unambiguously negative.
-
Laetrile for cancer: a systematic review of the clinical evidence
Supportive Care in Cancer, 2007Co-Authors: Stefania Milazzo, Stephane Lejeune, Edzard ErnstAbstract:Background Many cancer patients treated with conventional therapies also try ‘alternative’ cancer treatments. Laetrile is one such ‘alternative’ that is claimed to be effective by many alternative therapists. Laetrile is also sometimes referred to as amygdalin, although the two are not the same. Objective The aim of this review is to summarize all types of clinical data related to the effectiveness or safety of Laetrile interventions as a treatment of any type of cancer. Materials and methods All types of clinical studies containing original clinical data of Laetrile interventions were included. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (from 1951), EMBASE (from 1980), Allied and Complementary Medicine (AMED), Scirus, CancerLit, Cumulative Index to Nursing and Allied Health (CINAHL; all from 1982), CAMbase (from 1998), the MetaRegister, the National Research Register, and our own files. For reports on the safety of Laetrile, we also searched the Uppsala database. No language restrictions were imposed. Results Thirty six reports met our inclusion criteria. No controlled clinical trials were found. Three articles were nonconsecutive case series, 2 were consecutive case series, 6 were best case series, and 25 were case reports. None of these publications proved the effectiveness of Laetrile. Conclusion Therefore, the claim that Laetrile has beneficial effects for cancer patients is not supported by sound clinical data.
-
Laetrile for cancer a systematic review of the clinical evidence
Supportive Care in Cancer, 2007Co-Authors: Stefania Milazzo, Stephane Lejeune, Edzard ErnstAbstract:Background Many cancer patients treated with conventional therapies also try ‘alternative’ cancer treatments. Laetrile is one such ‘alternative’ that is claimed to be effective by many alternative therapists. Laetrile is also sometimes referred to as amygdalin, although the two are not the same.
Edzard Ernst - One of the best experts on this subject based on the ideXlab platform.
-
Laetrile treatment for cancer.
The Cochrane database of systematic reviews, 2011Co-Authors: Stefania Milazzo, Stephane Lejeune, Edzard Ernst, Katja Boehm, Markus HorneberAbstract:Laetrile is the name for a semi-synthetic compound which is chemically related to amygdalin, a cyanogenic glycoside from the kernels of apricots and various other species of the genus Prunus. Laetrile and amygdalin are promoted under various names for the treatment of cancer although there is no evidence for its efficacy. Due to possible cyanide poisoning, Laetrile can be dangerous. To assess the alleged anti-cancer effect and possible adverse effects of Laetrile and amygdalin. We searched the following databases: CENTRAL (2011, Issue 1); MEDLINE (1951-2011); EMBASE (1980-2011); AMED; Scirus; CancerLit; CINAHL (all from 1982-2011); CAMbase (from 1998-2011); the MetaRegister; the National Research Register; and our own files. We examined reference lists of included studies and review articles and we contacted experts in the field for knowledge of additional studies. We did not impose any restrictions of timer or language. Randomized controlled trials (RCTs) and quasi-RCTs. We searched eight databases and two registers for studies testing Laetrile or amygdalin for the treatment of cancer. Two review authors screened and assessed articles for inclusion criteria. We located over 200 references, 63 were evaluated in the original review and an additional 6 in this update. However, we did not identify any studies that met our inclusion criteria. The claims that Laetrile or amygdalin have beneficial effects for cancer patients are not currently supported by sound clinical data. There is a considerable risk of serious adverse effects from cyanide poisoning after Laetrile or amygdalin, especially after oral ingestion. The risk-benefit balance of Laetrile or amygdalin as a treatment for cancer is therefore unambiguously negative.
-
Laetrile for cancer: a systematic review of the clinical evidence
Supportive Care in Cancer, 2007Co-Authors: Stefania Milazzo, Stephane Lejeune, Edzard ErnstAbstract:Background Many cancer patients treated with conventional therapies also try ‘alternative’ cancer treatments. Laetrile is one such ‘alternative’ that is claimed to be effective by many alternative therapists. Laetrile is also sometimes referred to as amygdalin, although the two are not the same. Objective The aim of this review is to summarize all types of clinical data related to the effectiveness or safety of Laetrile interventions as a treatment of any type of cancer. Materials and methods All types of clinical studies containing original clinical data of Laetrile interventions were included. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (from 1951), EMBASE (from 1980), Allied and Complementary Medicine (AMED), Scirus, CancerLit, Cumulative Index to Nursing and Allied Health (CINAHL; all from 1982), CAMbase (from 1998), the MetaRegister, the National Research Register, and our own files. For reports on the safety of Laetrile, we also searched the Uppsala database. No language restrictions were imposed. Results Thirty six reports met our inclusion criteria. No controlled clinical trials were found. Three articles were nonconsecutive case series, 2 were consecutive case series, 6 were best case series, and 25 were case reports. None of these publications proved the effectiveness of Laetrile. Conclusion Therefore, the claim that Laetrile has beneficial effects for cancer patients is not supported by sound clinical data.
-
Laetrile for cancer a systematic review of the clinical evidence
Supportive Care in Cancer, 2007Co-Authors: Stefania Milazzo, Stephane Lejeune, Edzard ErnstAbstract:Background Many cancer patients treated with conventional therapies also try ‘alternative’ cancer treatments. Laetrile is one such ‘alternative’ that is claimed to be effective by many alternative therapists. Laetrile is also sometimes referred to as amygdalin, although the two are not the same.
Markus Horneber - One of the best experts on this subject based on the ideXlab platform.
-
Laetrile treatment for cancer
Cochrane Database of Systematic Reviews, 2015Co-Authors: Stefania Milazzo, Markus HorneberAbstract:BACKGROUND: Laetrile is an unconventional therapy which has been used illegally for decades by cancer patients who together with some alternative therapists claim its effectiveness as an anti-cancer treatment. It has been often referred to as amygdalin, although the two are not the same. OBJECTIVES: The aim of this review was to assess the alleged anti-cancer effect and the possible harms of Laetrile as a sole or adjunctive therapy in cancer treatment. SEARCH STRATEGY: We searched The Cochrane Central Register of Controlled Trials (CENTRAL); MEDLINE (from 1951); EMBASE (from 1980); Allied and Complementary Medicine (AMED), Scirus, CancerLit, CINAHL (all from 1982); CAMbase (from 1998); the MetaRegister; the National Research Register and our own files. No language restrictions were imposed. SELECTION CRITERIA: Randomized clinical trials (RCTs) and non randomized controlled clinical trials (non-RCTs). DATA COLLECTION AND ANALYSIS: Two reviewers independently assessed trials for inclusion in the review, assessed study quality and extracted data. MAIN RESULTS: No RCTs or non-RCTs were found, so no abstraction of outcome data could be performed in this systematic review AUTHORS' CONCLUSIONS: The claim that Laetrile has beneficial effects for cancer patients is not supported by data from controlled clinical trials. This systematic review has clearly identified the need for randomised or controlled clinical trials assessing the effectiveness of Laetrile or amygdalin for cancer treatment.
-
The Cochrane Library - Laetrile treatment for cancer
Cochrane Database of Systematic Reviews, 2015Co-Authors: Stefania Milazzo, Markus HorneberAbstract:Background Laetrile is the name for a semi-synthetic compound which is chemically related to amygdalin, a cyanogenic glycoside from the kernels of apricots and various other species of the genus Prunus. Laetrile and amygdalin are promoted under various names for the treatment of cancer although there is no evidence for its efficacy. Due to possible cyanide poisoning, Laetrile can be dangerous. Objectives To assess the alleged anti-cancer effect and possible adverse effects of Laetrile and amygdalin. Search methods We searched the following databases: CENTRAL (2014, Issue 9); MEDLINE (1951-2014); EMBASE (1980-2014); AMED; Scirus; CINAHL (all from 1982-2015); CAMbase (from 1998-2015); the MetaRegister; the National Research Register; and our own files. We examined reference lists of included studies and review articles and we contacted experts in the field for knowledge of additional studies. We did not impose any restrictions of timer or language. Selection criteria Randomized controlled trials (RCTs) and quasi-RCTs. Data collection and analysis We searched eight databases and two registers for studies testing Laetrile or amygdalin for the treatment of cancer. Two review authors screened and assessed articles for inclusion criteria. Main results We located over 200 references, 63 were evaluated in the original review, 6 in the 2011 and none in this update. However, we did not identify any studies that met our inclusion criteria. Authors' conclusions The claims that Laetrile or amygdalin have beneficial effects for cancer patients are not currently supported by sound clinical data. There is a considerable risk of serious adverse effects from cyanide poisoning after Laetrile or amygdalin, especially after oral ingestion. The risk–benefit balance of Laetrile or amygdalin as a treatment for cancer is therefore unambiguously negative.
-
Laetrile treatment for cancer.
The Cochrane database of systematic reviews, 2011Co-Authors: Stefania Milazzo, Stephane Lejeune, Edzard Ernst, Katja Boehm, Markus HorneberAbstract:Laetrile is the name for a semi-synthetic compound which is chemically related to amygdalin, a cyanogenic glycoside from the kernels of apricots and various other species of the genus Prunus. Laetrile and amygdalin are promoted under various names for the treatment of cancer although there is no evidence for its efficacy. Due to possible cyanide poisoning, Laetrile can be dangerous. To assess the alleged anti-cancer effect and possible adverse effects of Laetrile and amygdalin. We searched the following databases: CENTRAL (2011, Issue 1); MEDLINE (1951-2011); EMBASE (1980-2011); AMED; Scirus; CancerLit; CINAHL (all from 1982-2011); CAMbase (from 1998-2011); the MetaRegister; the National Research Register; and our own files. We examined reference lists of included studies and review articles and we contacted experts in the field for knowledge of additional studies. We did not impose any restrictions of timer or language. Randomized controlled trials (RCTs) and quasi-RCTs. We searched eight databases and two registers for studies testing Laetrile or amygdalin for the treatment of cancer. Two review authors screened and assessed articles for inclusion criteria. We located over 200 references, 63 were evaluated in the original review and an additional 6 in this update. However, we did not identify any studies that met our inclusion criteria. The claims that Laetrile or amygdalin have beneficial effects for cancer patients are not currently supported by sound clinical data. There is a considerable risk of serious adverse effects from cyanide poisoning after Laetrile or amygdalin, especially after oral ingestion. The risk-benefit balance of Laetrile or amygdalin as a treatment for cancer is therefore unambiguously negative.
Stephane Lejeune - One of the best experts on this subject based on the ideXlab platform.
-
Laetrile treatment for cancer.
The Cochrane database of systematic reviews, 2011Co-Authors: Stefania Milazzo, Stephane Lejeune, Edzard Ernst, Katja Boehm, Markus HorneberAbstract:Laetrile is the name for a semi-synthetic compound which is chemically related to amygdalin, a cyanogenic glycoside from the kernels of apricots and various other species of the genus Prunus. Laetrile and amygdalin are promoted under various names for the treatment of cancer although there is no evidence for its efficacy. Due to possible cyanide poisoning, Laetrile can be dangerous. To assess the alleged anti-cancer effect and possible adverse effects of Laetrile and amygdalin. We searched the following databases: CENTRAL (2011, Issue 1); MEDLINE (1951-2011); EMBASE (1980-2011); AMED; Scirus; CancerLit; CINAHL (all from 1982-2011); CAMbase (from 1998-2011); the MetaRegister; the National Research Register; and our own files. We examined reference lists of included studies and review articles and we contacted experts in the field for knowledge of additional studies. We did not impose any restrictions of timer or language. Randomized controlled trials (RCTs) and quasi-RCTs. We searched eight databases and two registers for studies testing Laetrile or amygdalin for the treatment of cancer. Two review authors screened and assessed articles for inclusion criteria. We located over 200 references, 63 were evaluated in the original review and an additional 6 in this update. However, we did not identify any studies that met our inclusion criteria. The claims that Laetrile or amygdalin have beneficial effects for cancer patients are not currently supported by sound clinical data. There is a considerable risk of serious adverse effects from cyanide poisoning after Laetrile or amygdalin, especially after oral ingestion. The risk-benefit balance of Laetrile or amygdalin as a treatment for cancer is therefore unambiguously negative.
-
Laetrile for cancer: a systematic review of the clinical evidence
Supportive Care in Cancer, 2007Co-Authors: Stefania Milazzo, Stephane Lejeune, Edzard ErnstAbstract:Background Many cancer patients treated with conventional therapies also try ‘alternative’ cancer treatments. Laetrile is one such ‘alternative’ that is claimed to be effective by many alternative therapists. Laetrile is also sometimes referred to as amygdalin, although the two are not the same. Objective The aim of this review is to summarize all types of clinical data related to the effectiveness or safety of Laetrile interventions as a treatment of any type of cancer. Materials and methods All types of clinical studies containing original clinical data of Laetrile interventions were included. We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (from 1951), EMBASE (from 1980), Allied and Complementary Medicine (AMED), Scirus, CancerLit, Cumulative Index to Nursing and Allied Health (CINAHL; all from 1982), CAMbase (from 1998), the MetaRegister, the National Research Register, and our own files. For reports on the safety of Laetrile, we also searched the Uppsala database. No language restrictions were imposed. Results Thirty six reports met our inclusion criteria. No controlled clinical trials were found. Three articles were nonconsecutive case series, 2 were consecutive case series, 6 were best case series, and 25 were case reports. None of these publications proved the effectiveness of Laetrile. Conclusion Therefore, the claim that Laetrile has beneficial effects for cancer patients is not supported by sound clinical data.
-
Laetrile for cancer a systematic review of the clinical evidence
Supportive Care in Cancer, 2007Co-Authors: Stefania Milazzo, Stephane Lejeune, Edzard ErnstAbstract:Background Many cancer patients treated with conventional therapies also try ‘alternative’ cancer treatments. Laetrile is one such ‘alternative’ that is claimed to be effective by many alternative therapists. Laetrile is also sometimes referred to as amygdalin, although the two are not the same.
Mohammed Helmy Faris Shalayel - One of the best experts on this subject based on the ideXlab platform.
-
beyond Laetrile vitamin b 17 controversy antitumor illusion or revolution
British Biomedical Bulletin, 2017Co-Authors: Mohammed Helmy Faris ShalayelAbstract:Many researchers have discovered amygdalin or Laetrile to be clinically inefficient in curing cancer, as well as potentially toxic or fatal when orally ingested due to cyanide poisoning. Nevertheless, hypotheses highlighted the role of amygdalin as an anticancer treatment causing programmed death in prostate cancer and human cervical cancer cells. Moreover, one study reported that amygdalin blocked bladder cancer cell growth by down-modulating the cell cycle regulating proteins cdk2 and cyclin A.
